Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2014 Jul;2(7):548-56.
doi: 10.1016/S2213-2600(14)70069-4. Epub 2014 Apr 21.

Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study

Collaborators, Affiliations
Clinical Trial

Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study

MeiLan K Han et al. Lancet Respir Med. 2014 Jul.

Erratum in

  • Lancet Respir Med. 2014 Aug;2(8):e14

Abstract

Background: The role of the lung microbiome in the pathogenesis of idiopathic pulmonary fibrosis is unknown. We investigated whether unique microbial signatures were associated with progression of idiopathic pulmonary fibrosis.

Methods: Patients (aged 35-80 years) with idiopathic pulmonary fibrosis within 4 years of diagnosis from the Correlating Outcomes with biochemical Markers to Estimate Time-progression (COMET) in idiopathic pulmonary fibrosis study were followed up for a maximum of 80 weeks. Progression-free survival was defined as time to death, acute exacerbation, lung transplant, or decrease in forced vital capacity (FVC) of 10% or greater or decrease in diffusion capacity of the lung (DLCO) of 15% or greater. DNA was isolated from 55 samples of bronchoscopic alveolar lavage. 454 pyrosequencing was used to assign operational taxonomic units (OTUs) to bacteria based on a 3% sequence divergence. Adjusted Cox models were used to identify OTUs that were significantly associated with progression-free survival at a p<0.10. These OTUs were then used in the analysis of the principal components. The association between principal components and microbes with high factor loadings and progression-free survival were assessed with Cox regression analyses. The COMET study is registered with ClinicalTrials.gov, number NCT01071707.

Findings: Mean FVC was 70.1% (SD 17.0) and DLCO 42.3% (14.0) of predicted. Disease progression was significantly associated with increased relative abundance of two OTUs-Streptococcus OTU 1345 (relative risk 1.11, 95% CI 1.04-1.18; p=0.0009) and Staphylococcus OTU 1348 (1.16, 1.03-1.31, p=0.012). Thresholds for relative abundance of each OTU associated with progression-free survival were more than 3.9% for Streptococcus OTU 1345 (10.19, 2.94-35.35; p=0.0002) and more than 1.8% for Staphylococcus OTU 1348 (5.06, 1.71-14.93; p=0.003).

Interpretation: These preliminary data suggest progression of idiopathic pulmonary fibrosis is associated with the presence of specific members within the Staphylococcus and Streptococcus genera. Additional research will be needed to identify the specific bacterial species and to ascertain whether this is a causal association.

Funding: National Institutes of Health.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest:

MH reports grants from NHLBI during the conduct of the study; grants and personal fees from GSK, personal fees from Pfizer, personal fees from BoehringerIngelheim, personal fees from Forest, personal fees from Novartis, personal fees from Medimmune, from Ikaria, personal fees from Regeneron, personal fees from Grifols, personal fees from Uptodate, outside the submitted work.

YZ, SM, and NT report grants from NIH during the conduct of this study.

IN reports grants from NIH during the conduct of the study. In addition, Dr. Noth has a patent TOLLIP SNPs in IPF pending.

VL and BM report no conflict of interest.

EW reports grants from the NIH during the conduct of this study.

KF reports personal fees and non-financial support from BoehringerIngelheim, during the conduct of the study; personal fees from BoehringerIngelheim, personal fees from Fibrogen, personal fees from Genentech, personal fees from Gilead, personal fees from Ikaria, personal fees from ImmuneWorks, personal fees from MedImmune, personal fees from Novartis, personal fees from Takeda, personal fees from Vertex, personal fees from Veracyte, personal fees from Roche, personal fees from Pulmonary Fibrosis Foundation, grants from ImmuneWorks, grants and personal fees from Intermune, grants from Bristol-Myers Squibb, personal fees from Glaxo Smith Klein, personal fees from Forest, personal fees from Up To Date, personal fees from NACE, personal fees from Excel, personal fees from France Foundation outside the submitted work.

GH reports reports grants from The National Institutes of Health during the conduct of the study.

FM reports grants from NHBLI, during the conduct of the study; personal fees from Able, personal fees from American Institute for Research, personal fees from Axon, personal fees from Grey Healthcare, personal fees from Merion, personal fees from Sudler& Hennessey, personal fees from Actelion, from Centocor, from Gilead, personal fees from Amgen, personal fees from Astra Zenneca, personal fees from Forest, personal fees from GSK, personal fees from Ikaria, personal fees from Jannsens, personal fees from Merck, personal fees from Nycomed/Takeda, personal fees from Pearl, personal fees from Pfizer, personal fees from Forest, personal fees from GSK, personal fees from Nycomed/Takeda, personal fees from American College of Chest Physicians, personal fees from Center for Healthcare Education, personal fees from CME Incite, personal fees from Inova, personal fees from MedScape/Web MD, personal fees from National Association for Continuing Education, personal fees from NCME, personal fees from Peer Voice, personal fees from Projects in Knowledge, personal fees from St. John's Hospital, personal fees from St. Mary's Hospital, personal fees from University of Illinois, Chicago, personal fees from University of Texas, Southwestern, personal fees from University of Virginia, personal fees from UpToDate, personal fees from Wayne State University, personal fees from Carden Jennings, personal fees from Ikaria, personal fees from MedImmune, personal fees from Nycomed/Takeda, personal fees from Vertex, personal fees and other from BoehringerIngelheim, personal fees from Bayer, personal fees from Forest, personal fees from GSK, personal fees from Nycomed/Takeda, personal fees from Prescott, personal fees from Informa, from Stromedix, from Promedior, personal fees from CSA Medical, personal fees from Miller Medical Communications, personal fees from Veracyte, outside the submitted work.

Figures

Figure 1
Figure 1
Figure 1A. Survival curves generated from Cox regression model stratified by threshold of 3·9% relative abundance for Streptococcus OTU 1345 with average patient profile values substituted for other covariates. Solid line indicates relative abundance below 3·9%; Dashed line indicates relative abundance above 3·9%. Number at risk at 100 day intervals displayed below the figure. Comparison of survival between patients with Streptococcus OTU 1345 below 3·9% relative abundance and patients with Streptococcus OTU 1345 above 3·9% relative abundance, adjusted for the following mean values: age-64·3 years; probability of being male-67·2%; probability of smoking (current and past)-67·3%; FVC%-70·1; DLCO%-42·3; probability of desaturation<88%-52·7%; probability of history of reflux-56·4%; and probability of having Staphylococcus OTU 1348 above threshold relative abundance-29% Figure 1B. Survival curves generated from Cox regression model stratified by threshold of 1·8% for Staphylococcus OTU 1348 with average patient profile values substituted for other covariates. Solid line indicates relative abundance below 1·8%; Dashed line indicates relative abundance above 1·8%. Number at risk at 100 day intervals displayed below the figure. Comparison of survival between patients with Staphylococcus OTU 1345 below 1·8% relative abundance and patients with Staphylococcus OTU 1345 above 1·8% relative abundance, adjusted for the following mean values: age-64·3 years; probability of being male-67·2%; probability of smoking (current and past)-67·3%; FVC%-70·1; DLCO%-42·3; probability of desaturation<88%-52·7%; probability of history of reflux-56·4%; and probability of having Streptococcus OTU 1348 above threshold relative abundance-14·5%
Figure 1
Figure 1
Figure 1A. Survival curves generated from Cox regression model stratified by threshold of 3·9% relative abundance for Streptococcus OTU 1345 with average patient profile values substituted for other covariates. Solid line indicates relative abundance below 3·9%; Dashed line indicates relative abundance above 3·9%. Number at risk at 100 day intervals displayed below the figure. Comparison of survival between patients with Streptococcus OTU 1345 below 3·9% relative abundance and patients with Streptococcus OTU 1345 above 3·9% relative abundance, adjusted for the following mean values: age-64·3 years; probability of being male-67·2%; probability of smoking (current and past)-67·3%; FVC%-70·1; DLCO%-42·3; probability of desaturation<88%-52·7%; probability of history of reflux-56·4%; and probability of having Staphylococcus OTU 1348 above threshold relative abundance-29% Figure 1B. Survival curves generated from Cox regression model stratified by threshold of 1·8% for Staphylococcus OTU 1348 with average patient profile values substituted for other covariates. Solid line indicates relative abundance below 1·8%; Dashed line indicates relative abundance above 1·8%. Number at risk at 100 day intervals displayed below the figure. Comparison of survival between patients with Staphylococcus OTU 1345 below 1·8% relative abundance and patients with Staphylococcus OTU 1345 above 1·8% relative abundance, adjusted for the following mean values: age-64·3 years; probability of being male-67·2%; probability of smoking (current and past)-67·3%; FVC%-70·1; DLCO%-42·3; probability of desaturation<88%-52·7%; probability of history of reflux-56·4%; and probability of having Streptococcus OTU 1348 above threshold relative abundance-14·5%
Figure 2
Figure 2
% Relative abundance of OTU’s from two IPF lung explants taken from proximal and distal airway brushings after the lung was removed. IPF Lung 1 demonstrated 100% relative abundance of Streptococcus OTU 1350 in the proximal brushing. In the distal brushing, two Streptococcus OTU’s were identified, OTU 1350 at 23.89% and OTU 1345 at 0.81% relative abundance. Staphylococcus OTU 1348 was also identified in the distal brush at 1.86% relative abundance. In IPF Lung 2, neither Streptococcus nor Staphylococcus was identified in the proximal brush, but the distal brush demonstrated 15.29% relative abundance for Streptococcus OTU 1345.

Comment in

References

    1. Noth I, Zhang Y, Swhu-Fan M, et al. Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. The Lancet Respiratory Medicine. 2013;1(4):309–17. - PMC - PubMed
    1. Fingerlin TE, Murphy E, Zhang W, et al. Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet. 2013;45(11):1409. - PMC - PubMed
    1. O'Dwyer DN, Armstrong ME, Trujillo G, et al. The Toll-like Receptor 3 L412F Polymorphism and Disease Progression in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2013;188(12):1442–50. - PubMed
    1. Peljto AL, Zhang Y, Fingerlin TE, et al. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA. 2013;309(21):2232–9. - PMC - PubMed
    1. Herazo-Maya JD, Noth I, Duncan SR, et al. Peripheral blood mononuclear cell gene expression profiles predict poor outcome in idiopathic pulmonary fibrosis. Sci Transl Med. 2013;5(205):205 ra136. - PMC - PubMed

Publication types

MeSH terms

Associated data

LinkOut - more resources